Stockscreener 앱 받기
3.29
7.19%
0.23
시간 외 거래:
3.29
Maxcyte Inc 주식(MXCT)의 최신 뉴스
US Bancorp DE Cuts Stock Holdings in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
Stifel Nicolaus Issues Pessimistic Forecast for MaxCyte (NASDAQ:MXCT) Stock Price - Defense World
What is William Blair’s Estimate for MaxCyte Q1 Earnings? - Defense World
MaxCyte files annual report with SEC By Investing.com - Investing.com Australia
MaxCyte core business revenue grows despite overall decline By Investing.com - Investing.com Australia
Stifel cuts MaxCyte stock price target to $9 from $11 By Investing.com - Investing.com Canada
Stifel cuts MaxCyte stock price target to $9 from $11 - Investing.com
MaxCyte stock touches 52-week low at $3.11 amid market challenges - Investing.com India
MaxCyte’s Promising Financial Outlook and Strategic Growth Justify Buy Rating - TipRanks
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2024 Earnings Call Transcript - Insider Monkey
MaxCyte price target lowered to $6 from $8 at BTIG - TipRanks
MaxCyte stock price target cut to $6 at BTIG By Investing.com - Investing.com South Africa
MaxCyte price target lowered to $9 from $11 at Stifel - TipRanks
MaxCyte stock price target cut to $6 at BTIG - Investing.com India
MaxCyte files annual report with SEC - Investing.com India
MaxCyte core business revenue grows despite overall decline - Investing.com India
Maxcyte Sees 2025 Core Revenue To Grow 8% To 15% -March 12, 2025 at 03:20 am EDT - Marketscreener.com
MaxCyte reports a return to core revenue growth in FY24 - DirectorsTalk Interviews
MaxCyte Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MaxCyte’s Strategic Expansion and Financial Resilience Drive Buy Rating - TipRanks
MaxCyte shares tumble as Q4 revenue plunges despite beating estimates By Investing.com - Investing.com Australia
MaxCyte shares tumble as Q4 revenue plunges despite beating estimates - Investing.com India
MaxCyte reports Q4 EPS (10c), consensus (12c) - TipRanks
MAXCYTE, INC. SEC 10-K Report - TradingView
MaxCyte Reports 2024 Financial Results with Core Growth - TipRanks
MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance - The Manila Times
MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 ... - Bluefield Daily Telegraph
MaxCyte (MXCT) Expected to Announce Quarterly Earnings on Tuesday - Defense World
MaxCyte® acquires SeQure Dx to broaden cell engineering offerings with on-target and off-target editing assessments - MSN
MaxCyte Expands Stock Capital with New Issuance - TipRanks
MaxCyte, Inc.'s (LON:MXCT) Stock Retreats 26% But Revenues Haven't Escaped The Attention Of Investors - Simply Wall St
Institutional owners may take dramatic actions as MaxCyte, Inc.'s (LON:MXCT) recent 11% drop adds to one-year losses - Simply Wall St
MaxCyte: Building the Future of Cell and Gene Therapy Innovation - MSN
Andrew Mancini, PhD's Profile Page - Technology Networks
263,833 Shares in MaxCyte, Inc. (NASDAQ:MXCT) Bought by Rice Hall James & Associates LLC - MarketBeat
TG Therapeutics advancing CAR T-cell therapy toward Phase 1 trial - Multiple Sclerosis News Today
MaxCyte Experiences Shift in Major Holdings by BlackRock - TipRanks
BlackRock Increases Stake in MaxCyte to 7.66% - TipRanks
Bio Buyout: MaxCyte Acquires SeQure - Law Street Media
BlackRock Adjusts Holdings in MaxCyte, Inc. - TipRanks
TG Therapeutics to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy program, for the treatment of autoimmune diseases - MSN
TG Therapeutics to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform - News-Medical.Net
TG Therapeutics Licenses Maxcyte Tech to Develop Cell Therapies for Autoimmune Disease - Genetic Engineering & Biotechnology News
MaxCyte Signs Licensing Deal With TG Therapeutics For Next-Gen Autoimmune Cell Therapies - Nasdaq
MaxCyte signs SPL deal with TG Therapeutics - ShareCast
MaxCyte Signs Platform License Deal With TG Therapeutics -February 12, 2025 at 05:07 am EST - Marketscreener.com
MaxCyte, TG Therapeutics sign strategic platform license to advance autoimmune cell therapeutics programs - MSN
MaxCyte Licenses Cell-Engineering Technology to TG Therapeutics -February 12, 2025 at 04:37 am EST - Marketscreener.com
MaxCyte and TG Therapeutics partner on next-gen cell therapy for MS - DirectorsTalk Interviews
MaxCyte Partners with TG Therapeutics for Autoimmune Cell Therapy - TipRanks
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs - The Manila Times
Maxcyte Says Enters Strategic Platform License With TG Therapeutics -February 12, 2025 at 02:18 am EST - Marketscreener.com
MaxCyte Enters Strategic License Agreement with TG Therapeutics for Cell-Based Therapy Development - Nasdaq
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell - The Bakersfield Californian
Major Autoimmune Breakthrough: MaxCyte Technology Powers Next-Gen Multiple Sclerosis Treatment - StockTitan
Boston-area diagnostics startup scooped up by Maryland company - The Business Journals
2.18%
자본화:
|
볼륨(24시간):